2016-02-26 05:14:27 – Biological Hazard – USA


RSOE EDIS ALERTMAIL
RSOE Emergency and Disaster Information Service
Budapest, Hungary
2016-02-26 05:14:27 – Biological Hazard – USA
EDIS Code: BH-20160226-52242-USA
Date&Time: 2016-02-26 05:14:27 [UTC]
Continent: North-America
Country: USA
State/Prov.: State of New Jersey,
Location: Shore Medical Center,
City: Somers Point
Number of infected people: 200
More than 200 people treated at a New Jersey medical center may have been exposed to HIV or hepatitis B or C because of a former employee accused of tampering with drugs, the hospital said on Thursday. Shore Medical Center in Somers Point, located on the southern New Jersey coast outside of Atlantic City, sent letters last week to 213 patients who were treated with certain intravenous medications, including morphine, between June 1, 2013 and Sept. 17, 2014. “We have been working with public health authorities to determine if patients could have been exposed to blood-borne pathogens at Shore through contact with this employee’s blood,” said hospital spokesman Brian Cahill in a statement. Free testing and support are being offered to the patients, the hospital said. New Jersey Health Department spokeswoman Dawn Thomas described the risk of exposure as low. Frederick McLeish, 53, a former pharmacist at the hospital, is accused of removing the drugs from vials intended to be used in the preparation of intravenous medications for patients, and replacing them with a saline solution. His attorney, John Zarych, declined to comment on the case. The hospital detected a problem and fired McLeish, of Egg Harbor Township, after an internal investigation. On Jan. 21 he was indicted by an Atlantic County grand jury on charges of drug tampering, theft and drug possession. He was released on bail the same day, according to a court official. On Monday, McLeish was arraigned in Atlantic County Superior Court. A status hearing, at which he is expected to enter a plea, has been scheduled for March 7. McLeish had been authorized to prescribe, dispense or administer medication, according to the Atlantic County prosecutor’s office. The hospital, state health department and Centers for Disease Control and Prevention are still investigating.
The name of Hazard: HIV or hepatitis B or C infection
Species: Human
Status: Confirmed
Posted:2016-02-26 05:14:27 [UTC]

Advertisements

CDC Warning, Just In From CDC “Simulated IV Fluids Continues”


Investigation into Patients Being Injected with Simulated IV Fluids Continues

FDA and the Centers for Disease Control and Prevention (CDC) are continuing to investigate multiple instances of Wallcur’s simulated intravenous (IV) saline products being administered to patients. These products are NOT sterile and should NOT be injected in humans or animals. FDA has posted an update on the investigation on its website, which may be found at http://www.fda.gov/Drugs/DrugSafety/ucm428431.htm.

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

Investigation into Patients Being Injected with Simulated IV Fluids Continues

FDA and the Centers for Disease Control and Prevention (CDC) are continuing to investigate multiple instances of Wallcur’s simulated intravenous (IV) saline products being administered to patients. These products are NOT sterile and should NOT be injected in humans or animals. FDA has posted an update on the investigation on its website, which may be found at http://www.fda.gov/Drugs/DrugSafety/ucm428431.htm.
As a reminder, Wallcur’s simulated IV saline solution, Practi-0.9% sodium chloride solution, was shipped to medical clinics, surgical centers, and urgent care facilities in numerous states. So far, more than 40 patients have received infusions of the simulated saline products, and there have been many adverse events associated with these incidents including fever, chills, tremors and headache. Some patients were hospitalized, and there is one death associated with the use of these products; it is not known if this death is directly related to the use of the product. Adverse events have been reported in seven states: Florida, Georgia, Idaho, Louisiana, North Carolina, New York, and Colorado.

ucm428435

Investigation into Patients Being Injected with Simulated IV Fluids Continues

FDA and the Centers for Disease Control and Prevention (CDC) are continuing to investigate multiple instances of Wallcur’s simulated intravenous (IV) saline products being administered to patients. These products are NOT sterile and should NOT be injected in humans or animals. FDA has posted an update on the investigation on its website, which may be found at http://www.fda.gov/Drugs/DrugSafety/ucm428431.htm.
As a reminder, Wallcur’s simulated IV saline solution, Practi-0.9% sodium chloride solution, was shipped to medical clinics, surgical centers, and urgent care facilities in numerous states. So far, more than 40 patients have received infusions of the simulated saline products, and there have been many adverse events associated with these incidents including fever, chills, tremors and headache. Some patients were hospitalized, and there is one death associated with the use of these products; it is not known if this death is directly related to the use of the product. Adverse events have been reported in seven states: Florida, Georgia, Idaho, Louisiana, North Carolina, New York, and Colorado.

To view the full, updated alert on this important situation, please visit http://www.fda.gov/Drugs/DrugSafety/ucm428431.htm.

As a reminder, Wallcur’s simulated IV saline solution, Practi-0.9% sodium chloride solution, was shipped to medical clinics, surgical centers, and urgent care facilities in numerous states. So far, more than 40 patients have received infusions of the simulated saline products, and there have been many adverse events associated with these incidents including fever, chills, tremors and headache. Some patients were hospitalized, and there is one death associated with the use of these products; it is not known if this death is directly related to the use of the product. Adverse events have been reported in seven states: Florida, Georgia, Idaho, Louisiana, North Carolina, New York, and Colorado.

To view the full, updated alert on this important situation, please visit http://www.fda.gov/Drugs/DrugSafety/ucm428431.htm.